Caregen PTx delivers a first in science history

8 Aug 2019

Caregen has developed a new Botulinum Toxin Type C peptide (PTx) for revolutionary topical applications which are effective in wrinkles, acne, pore & sebum control, hyperhidrosis, atopic dermatitis, muscle and chronic pain relief.

Whereas the traditional botulinum toxin product is toxin type A which only cleaves SNAP-25 of the Snare Complex, PTx is the first botulinum toxin type C peptide in terms of its mechanism which cleaves both SNAP-25 and Syntaxin.

Caregen PTx delivers a first in science history


This is the first report of protein cleavage peptide in science history and PTx blocks acetylcholine release, a neurotransmitter secreted from nerve cells like the botulinum toxin mechanism. By this mechanism, PTx also regulates inflammatory cytokines caused by excessive exercise, neural and muscle damage and surprisingly relieves muscle and chronic pain in 5 min.

PTx Sports is a muscle and chronic pain relief product which is user- friendly with the formulation of no stickiness and odorless and it is not comparable with any other topical pain relief products in the market in terms of efficacy and the science behind them.

The IP protected PTx can be extended to more than 500 innovative and exclusive topical product lines which nobody can copy for next 20 years.

Caregen is a Korean public biotech company based on platform technology of global leading biomimetic peptides. The company has developed about 600 peptides (190 global patents) for various applications in cosmeceutical and pharmaceutical uses for last 18 years.

For more information on PTx, please visit Caregen at the Booth No. 42C06 at CPhi Worldwide.